Health-system specialty pharmacy role and outcomes: A review of current literature
- PMID: 35916907
- DOI: 10.1093/ajhp/zxac212
Health-system specialty pharmacy role and outcomes: A review of current literature
Abstract
Purpose: Specialty medications can have life-altering outcomes for patients with complex diseases. However, their benefit relies on appropriate treatment selection, patients' ability to afford and initiate treatment, and ongoing treatment optimization based on patient response to therapy. Mounting research demonstrates the benefits of the health-system specialty pharmacies (HSSPs) in improving specialty medication access, affordability, and outcomes. The purpose of this rapid review is to describe the currently reported role and function of HSSP pharmacists and outcomes reported with use of the HSSP model, and to identify gaps in the literature where more information is needed to better understand the HSSP model and outcomes.
Summary: Current literature describes the role of HSSP pharmacists in facilitating patient access, affordability, and initiation and maintenance of specialty medications. Though it is clear HSSP pharmacists are involved in treatment monitoring, often through utilizing the electronic health record, more information is needed to elucidate the frequency, method, and extent of monitoring. Despite several valuable continuity of care services reported to be provided by HSSPs, the breadth and degree of standardization of these services remains unclear. There is minimal literature describing HSSP education and research involvement. HSSPs have reported significant benefits of this patient care model, as demonstrated by higher adherence and persistence; better clinical outcomes; financial benefits to patients, payers, and the health system; better quality of care; higher patient and provider satisfaction with services, and highly efficient specialty pharmacy services. More literature comparing clinical and diagnosis-related outcomes in HSSP versus non-HSSP patients is needed.
Conclusion: HSSPs provide comprehensive, patient-centered specialty medication management that result in improved care across the continuum of the specialty patient journey and act as a valuable resource for specialty clinics and patients beyond medication management. Future research should build on the current description of HSSP services, how services affect patient outcomes, and the impact HSSP network restrictions.
Keywords: access; and evaluation; healthcare quality; integrated delivery of healthcare; pharmacy; specialty pharmacy.
© American Society of Health-System Pharmacists 2022. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
2022 ASHP Survey of Health-System Specialty Pharmacy Practice: Clinical Services.Am J Health Syst Pharm. 2023 Jun 22;80(13):827-841. doi: 10.1093/ajhp/zxad064. Am J Health Syst Pharm. 2023. PMID: 36999452
-
Development, implementation, and evaluation of a health outcomes and research program at an integrated health-system specialty pharmacy.Am J Health Syst Pharm. 2021 May 24;78(11):972-981. doi: 10.1093/ajhp/zxab082. Am J Health Syst Pharm. 2021. PMID: 33693451 Free PMC article.
-
Advancing Patient Care Through Specialty Pharmacy Services in an Academic Health System.J Manag Care Spec Pharm. 2017 Aug;23(8):815-820. doi: 10.18553/jmcp.2017.23.8.815. J Manag Care Spec Pharm. 2017. PMID: 28737983 Free PMC article.
-
Integrated clinical and specialty pharmacy practice model for management of patients with multiple sclerosis.Am J Health Syst Pharm. 2014 Mar 15;71(6):463-9. doi: 10.2146/ajhp130495. Am J Health Syst Pharm. 2014. PMID: 24589537 Review.
-
Defining and advancing ambulatory care pharmacy practice: it is time to lengthen our stride.Am J Health Syst Pharm. 2014 Aug 15;71(16):1348-56. doi: 10.2146/ajhp140076. Am J Health Syst Pharm. 2014. PMID: 25074954 Review.
Cited by
-
Low rates of primary medication nonadherence in patients prescribed oral oncology agents across health system specialty pharmacies.J Manag Care Spec Pharm. 2023 Jul;29(7):740-748. doi: 10.18553/jmcp.2023.29.7.740. J Manag Care Spec Pharm. 2023. PMID: 37404071 Free PMC article.
-
Patient-Tailored Interventions to Improve Specialty Medication Adherence: Results from a Prospective Randomized Controlled Trial.Am J Med. 2023 Jul;136(7):694-701.e1. doi: 10.1016/j.amjmed.2023.03.007. Epub 2023 Apr 5. Am J Med. 2023. PMID: 37028694 Free PMC article. Clinical Trial.
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer.Breast Cancer Res Treat. 2025 Jul;212(1):71-78. doi: 10.1007/s10549-025-07701-x. Epub 2025 Apr 16. Breast Cancer Res Treat. 2025. PMID: 40237878
-
Ustekinumab infusion to subcutaneous transition: Coordinating care and identifying potential gaps.J Manag Care Spec Pharm. 2025 Aug;31(8):764-771. doi: 10.18553/jmcp.2025.31.8.764. J Manag Care Spec Pharm. 2025. PMID: 40704856 Free PMC article.
-
Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative.J Manag Care Spec Pharm. 2024 Jul;30(7):710-718. doi: 10.18553/jmcp.2024.30.7.710. J Manag Care Spec Pharm. 2024. PMID: 38950163 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources